Fareon microtesla magnetic therapy shows cognitive improvement in long COVID brain fog — RCT published
Summary
Fareon published a randomized controlled feasibility study of their microtesla-range transcranial magnetic field therapy for cognitive impairment in post-acute sequelae of SARS-CoV-2 (long COVID brain fog) on medRxiv. The ultra-low-intensity magnetic field approach — mechanistically targeting neuroinflammation and oxidative stress through ROS-sensitive ion channels as published in Cell (December 2025) — showed improvements in cognitive test scores and self-reported brain fog severity in the feasibility trial. The long COVID application extends Fareon's anti-neuroinflammatory mechanism to a large and underserved patient population.
Why it matters
Long COVID brain fog affects an estimated 10-15 million people globally with no approved treatments. A non-invasive, ultra-low-intensity magnetic field therapy showing cognitive improvement in an RCT — even a feasibility study — is immediately newsworthy given the absence of alternatives. Fareon's Cell mechanism paper plus feasibility RCT provides a credible scientific basis for a full-scale efficacy trial.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial